Skip to main content
. 2022 Aug 5;9:1632–1638. doi: 10.1016/j.toxrep.2022.07.018

Fig. 1.

Fig. 1

Viability studies with Peptide 14 tested on human skin cells and 3D skins equivalents. Different cell lines and 3D skin equivalents were exposed to Peptide 14 at several concentrations and cell viability was assessed after 24–42 h using MTT assay. A.1) Cell viability of human dermal fibroblasts, graphs represent the average of 3 donors (35, 55 and 60 y) A.2) Cell viability of human keratinocytes, graphs represent the average of 3 donors (35, 55, and 60 y). B.1) Cell viability of 3D skin human equivalents treated topically with different concentrations of Peptide 14. B.2) Representative images of H&E staining of 3D skin equivalent. Scale bar: 200 µm. C.1) Cell viability of 3D skin human equivalents treated in the media with different concentrations of Peptide 14. C.2) Representative images of H&E staining of 3D skin equivalent. Scale bar: 200 µm. All experiments were performed in triplicate and were analyzed using ONE way anova and Bonferroni post-hoc test. * **p < 0.001; * ** *p < 0.0001, represents a significant difference compared to untreated controls.